Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 953-955

  Takegawa, N ^a   Hayashi, H ^a   Iizuka, N ^b   Takahama, T ^a   Ueda, H ^a   Tanaka, K ^a   Takeda, M ^a   Nakagawa, K ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kishiwada City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CD56 ANTIGEN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PEMETREXED; SYNAPTOPHYSIN; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ALK GENE; BRAIN METASTASIS; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC TRANSFORMATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; LUNG BIOPSY; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; SMALL CELL LUNG CANCER; THORACOSCOPY; TREATMENT RESPONSE; ADENOCARCINOMA; CELL TRANSFORMATION; DISEASE EXACERBATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; CARBAZOLES; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SMALL CELL LUNG CARCINOMA;

EID: 84964711762     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw032     Document Type: Letter

References (4)

1. Isozaki H, Takigawa N, Kiura K. Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers (Basel) 2015; 7: 763-783.
2. Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 2015; 4: 67-81.
3. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-smallcell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-e172.
4. Niederst MJ, Sequist LV, Poirier JT et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015; 6: 6377.